Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers

被引：0
|
作者：
Yoshida, Ryohei
Okumura, Shunsuke
Sasaki, Takaaki
Osaki, Yoshinobu
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2121
引用
收藏
页数：3
相关论文
共 50 条
  • [21] ALK-rearranged Non-Small Cell Lung Cancer Cystic Brain Metastases
    Lakhani, Dhairya A.
    Deng, Francis
    RADIOLOGY, 2024, 313 (01)
  • [22] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1474 - 1474
  • [23] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 830 - 830
  • [24] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
  • [25] Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
    Yun, Mi Ran
    Choi, Hun Mi
    Lee, You Won
    Joo, Hyeong Seok
    Park, Chae Won
    Choi, Jae Woo
    Kim, Dong Hwi
    Kang, Han Na
    Pyo, Kyoung-Ho
    Shin, Eun Joo
    Shim, Hyo Sup
    Soo, Ross A.
    Yang, James Chih-Hsin
    Lee, Sung Sook
    Chang, Hyun
    Kim, Min Hwan
    Hong, Min Hee
    Kim, Hye Ryun
    Cho, Byoung Chul
    EMBO MOLECULAR MEDICINE, 2019, 11 (12)
  • [26] ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Girard, Nicolas
    Audigier-Valette, Clarisse
    Cortot, Alexis B.
    Mennecier, Bertrand
    Debieuvre, Didier
    Planchard, David
    Zalcman, Gerard
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Barlesi, Fabrice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (02) : 225 - 233
  • [27] Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients
    Clave, S.
    Salido, M.
    Gibert, J.
    Hardy-Werbin, M.
    Weingartner, E.
    Hernandez, J.
    Nichol, D.
    Rocha, P.
    Riera, X.
    Blanco, R.
    Bosch-Barrera, J.
    Taus, A.
    Pijuan, L.
    Bellosillo, B.
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S508 - S509
  • [28] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [29] Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer
    Pailler, Emma
    Faugeroux, Vincent
    Oulhen, Marianne
    Mezquita, Laura
    Laporte, Melanie
    Honore, Aurelie
    Lecluse, Yann
    Queffelec, Pauline
    NgoCamus, Maud
    Nicotra, Claudio
    Remon, Jordi
    Lacroix, Ludovic
    Planchard, David
    Friboulet, Luc
    Besse, Benjamin
    Farace, Francoise
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6671 - 6682
  • [30] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
12345